Fig. 6From: Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse modelsExpression patterns of soluble urokinase-type plasminogen activator receptor (suPAR) variants in clinical subjects. Immunoblot analyses of expressions of serum suPAR variants in minimal-change disease (MCD) and focal segmental glomerulosclerosis (FSGS) clinical subjects are presentedBack to article page